A plethora of literature points to the association between these mutations and resistance to common therapies especially anti-EGFR treatment as well as cancer progression (16), highlighting the need to detect PIK3CA p110α mutation as a strong predictive and prognostic biomarker. The gene discussed is EGFR; the disease is cancer.